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Background
The HIV-1 envelope glycoprotein (Env) on the viral sur-
face is the target for anti-HIV-1 neutralizing antibodies.
In some HIV-1 infected patients broadly neutralizing
antibodies (BrNAb) develop that neutralise HIV-1 from
different subtypes and therefore are considered to be
directed against conserved regions [2]. The most vulner-
able epitopes can be shielded from antibody recognition
by steric hindrance and N-linked glycans [3]. Moreover,
length and glycosylation of the envelope V1V2 region
seem to play a role in resistance against neutralizing
antibodies [4]. Understanding of factors involved in
BrNAb development will help the rational design of an
effective antibody-based vaccine immunogen.
Methods
From a previous screening of 299 patients for broadly
neutralizing activity (BrNAc), we selected 13 patients
with high BrNAc in serum, 9 patients without BrNAc
(non-BrNAc) and 10 patients with intermediate BrNAc,
at 2-4 years after SC. From these patients clonal viruses
were obtained within the first year after SC from which
gp160 was sequenced and analyzed for length of differ-
ent regions and number of potential N-linked glycosyla-
tion sites (PNGS). Additionally we tested the
neutralization sensitivity of the viral variants from the
patients with and without BrNAc against different
already identified broadly neutralizing antibodies
(BrNAbs).
Results
We observed a correlation between length of the vari-
able regions 1 and 2 (V1V2) of env,e s p e c i a l l yf o rv a r i -
able region 1 (V1), and the presence of BrNAc. Patients
with non-BrNAc in their serum had HIV-1 variants
with longer V1 regions. Remarkably, differences in
length of the V1 region did not coincide with differences
in the number of PNGS on V1. Only the number of
PNGS in gp41 correlated with BrNAc, where a higher
number of PNGS correlated with the absence of BrNAc.
No significant differences were observed between HIV-1
variants from individuals with and without BrNAc in
their sensitivity to the known BrNAbs b12, 2G12, 2F5,
4E10, PG9, PG16 and VRCO1.
Conclusion
The observed correlation between a shorter V1 of env in
patients with BrNAc could indicate that the develop-
ment of BrNAc in HIV-1 infected patients is associated
with a more accessible and more open structure of the
viral envelope glycoprotein, which is achieved by having
fewer glycans and shorter variable loops. However these
env characteristics on early viruses isolated from
patients who developed BrNAc did not coincide with a
higher sensitivity to BrNAbs as compared to early
v i r u s e sf r o mp a t i e n t sw h od i dn o td e v e l o p e dB r N A c .
Identification of env characteristics that coincide with
BrNAc in patients could help the rational design of an
effective antibody-based vaccine immunogen.
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